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Abstract
Background: Tourette Syndrome (TS) is a highly prevalent childhood neuropsychiatric disorder (about 1 %),
characterized by multiple motor and one or more vocal tics. The syndrome is commonly associated to comorbid
conditions (e.g., Attention Deficit Hyperactivity Disorder and Obsessive Compulsive Disorder), which considerably
aggravate clinical symptoms and complicate diagnosis and treatment. To date, TS molecular bases are unknown
and its molecular diagnosis is unfeasible.
Results: Due to their master role within cell networks and pathways both in physiology as in pathology, we sought
to determine the transcriptome of circulating miRNAs in TS patients: by TaqMan Low Density Arrays, we profiled
the expression in serum of 754 miRNAs in six TS patients and three unaffected controls (NCs) (discovery set). These
data were validated by single TaqMan assays on serum from 52 TS patients and 15 NCs (validation set). Network
and Gene-ontology analysis were performed by using Cytoscape and Babelomics server. We found that miR-429 is
significantly underexpressed in TS patients with respect to NCs. Decreased serum levels of miR-429 allowed us to
discriminate TS patients from NCs with 95 % of sensitivity and 42 % of specificity. Intriguingly, computational
analysis of the network comprising miR-429 targets demonstrates their involvement in differentiation of midbrain
and hindbrain and synaptic transmission.
Conclusions: Our data open the way to further molecular characterization of TS and eventual identification of the
corresponding genotypes. Circulating miR-429 may be immediately useful as sensitive molecular biomarker to
support TS diagnosis, actually based only on DSM-V criteria.
Keywords: Tourette syndrome, Circulating miRNAs, Molecular pathogenesis, Molecular biomarkers, Minimally
invasive molecular diagnosis
Background
Gilles de la Tourette Syndrome (TS) is a highly prevalent
childhood neurodevelopmental disorder, characterized by
both multiple motor and vocal tics: these appear during
illness, not necessarily concurrently [1]. Tics are sudden,
rapid, recurrent, non rhythmic movements or vocaliza-
tions, which wax and wane in frequency; to be
diagnostically useful, they must have persisted for more
than 1 year since onset (Diagnostic and Statistical Manual
of Mental Disorders, DSM-V) [1, 2]. TS prevalence is esti-
mated to be about 1 % [2]. The syndrome is commonly as-
sociated to comorbid conditions as Attention Deficit
Hyperactivity Disorder (ADHD) and Obsessive Compul-
sive Disorder (OCD) [2], which have been reported in 60,
and 45–60 % of TS patients, respectively [3]: both ADHD
and OCD sensibly impair their health-related quality of
life [4–6]. The most disabling of them is OCD, which also
causes poor self-esteem and low quality of life [7]. It has
been stressed that these comorbidities should be
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considered as negative prognostic factors, given that they
considerably worsen prognosis [7–9]. Different TS symp-
toms are associated with dysfunctions of distinct cortical
areas: this has clear implications for the neuroanatomical
model of the syndrome [10]. TS has a multifactorial
etiology, in which genetic, neurological and environmental
factors interact to determine the clinical phenotype [1].
Several genetic mutations have been suggested to be
involved in TS (e.g., those at the SLITRK1 locus or at loci
of genes belonging to dopaminergic and serotoninergic
pathways) [1, 11]. MicroRNAs (miRNAs) are small non
protein-coding RNAs (19–25 nucleotides long), which
negatively regulate gene expression at the post-
transcriptional level [12, 13]. MiRNAs are master regula-
tors of cellular pathways and networks: accordingly, they
perform key roles in different biological processes and dis-
eases [14, 15]. Serum/circulating miRNAs (cmiRNAs) have
been detected in all body fluids analyzed to date [16, 17]:
this discovery has disclosed the possibility of identifying
minimally invasive biomarkers of disease through liquid
biopsies [18]. In psychiatric diseases, this approach has
been already applied to Autism [19], Bipolar Disorder [20],
Schizophrenia [21], Depression [22], but not to TS. We hy-
pothesized that altered cmiRNAs serum profiles could be
identified also in TS and hint to its biomolecular bases;
furthermore and equally important, these molecular data
could be immediately applied to strengthen traditional TS
diagnosis, actually based on DSM-V criteria. Through a
high throughput approach, we identified a cmiRNA differ-
entially expressed (DE) in sera from TS patients with
respect to healthy controls. After performing a computa-
tional analysis of its target mRNAs, we discovered that
these encode proteins that are involved in differentiation of
midbrain and hindbrain and synaptic transmission.
Results
Demographic data
Fifty eight young caucasian people affected by TS [mean
age 12.7 y (SD ±0.9), sex M : F = 50:8] and 18 unaffected
controls (NCs) [mean age 12.2 y (SD ± 0.9), sex M : F =
14:4] were recruited into the study. Age distribution was
not significantly different within the TS cohort respect
to NCs (p-value: 0.170). 87.5 % of TS patients and
73.3 % NCs were males: also this difference is not statis-
tically significant (p-value 0.178) (Table 1).
Neuropsychiatric findings in TS patients
All TS patients presented DCI > 80 % (mean score 87.6 %,
SD ± 7.6). Concerning YGTSS (Yale Global Tic Severity
Rating Scale), patients presented a mean total tic score
of 29.7 (SD ± 7.1) and a mean impairment score of 27.9
(SD ± 8.7). The mean C-YBOCS (Children’s Yale-Brown
Obsessive Compulsive Scale) score was 18.3 (SD ± 8.7)
(Table 2). Many patients (39 out 58:67 %) required
pharmacological treatment with SSRI, neuroleptics or
both. We detected a statistically significant difference in
CADS (Conner’s ADHD/DSMV-IV Scale) score be-
tween TS patients and NCs (p-value 0.000) (Table 2).
MiRNAs profile in TS patients
Through TaqMan Low Density Array (TLDA) analysis, we
determined the total expression profiles of 754 miRNAs in
sera from six TS patients and three unaffected controls.
Real time experiments were separately performed for flu-
idic card A and B: each card contained 384 TaqMan as-
says. Cycle thresholds (Cts) obtained for each sample for
each miRNA were used to calculated DCt, which were
computed by the SAM method to identify differentially
expressed (DE) miRNAs (Additional file 1). We found that
only miR-429 was differentially expressed: it was signifi-
cantly downregulated in serum of TS patients with respect
to NCs by using both GMN method and miR-320 as en-
dogenous control (FDR = 0.024).
Validation by single TaqMan assays
Expression of miR-429 was subjected to validation
through single TaqMan assays in serum of 52 TS patients
and 15 NCs. By applying both parametric (t-test) and non
parametric (Wilcoxon test) tests, we confirmed the statis-
tically significant downregulation of miR-429 in TS pa-
tients with respect to NCs (Wilcoxon test p-value = 0.01;
t-test p-value = 0.004) (Fig. 1). By computing a ROC curve,
we found that the decrease of miR-429 serum levels was
able to discriminate TS patients from NCs. Specifically, we
obtained an AUC of 0.75 (95 % CI, 0.584‑0.907; p = 0.01),
with 95 % of sensitivity and 42 % of specificity (DCt cut-
off value: 10.32) (Fig. 2).
Correlation between miR-429 expression and
neuropsychiatric parameters
To evaluate whether expression changes of miR-429
were associated with the clinical and pathologic charac-
teristics observed in patients, its expression levels were
compared to different parameters including C-YBOCS,
YGTSS, Conner’s ADHD. However, we found only a
weak positive correlation between Conner’s ADHD and
miR-429 expression (Pearson = 0.28; pvalue = 0.03), while
Table 1 Clinical features
TS NCs p-value*
Sex M:F 50:8 14:4 0.178
Mean age 12.7 (±0.9) 12.2 (±2.1) 0.170
Mean age at onset 5.9 (±1.91)
Ethnic Background: Caucasian 58 18
TS: Tourette Syndrome
NC: Normal Controls
Standard Deviation is shown between parenthesis
*statistical significance p < 0.05
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there were no significant associations among miRNAs
expression and C-YBOCS and YGTSS scores. Next, we
assigned the expression levels of miR-429 to comorbidity
groups: (TS + OCD: 20 patients), (TS + ADHD: 13 pa-
tients), (TS + ADHD + OCD: 16 patients). We com-
pared the expression of miR-429 among different
comorbidity groups and patients with no comorbidity
(Fig. 3). We found no statistically significant difference
of expression among these groups, although patients
with TS+ADHD+OCD showed a downregulation of
miR-429 slightly more pronounced than other groups.
MiRNA targets identification and network analysis
To pinpoint the biological functions of miR-429 and ra-
tionalize its etiological involvement in TS, we computa-
tionally retrieved its validated targets (26 targets based
on TarBase); we then built a molecular network com-
prising miR-429 validated targets and their first neigh-
bours. The generated network, consisting of 1472 nodes
and 11,532 edges, was topologically centred on BCL2,
CREBBP, EP300, HNF4A, MYC (network nodes with
highest degree and betweenness). By using FatiGO en-
richment analysis tool, we compared the statistically
overrepresented biological functions of all nodes within
the network against the entire genome; the following data-
bases were analyzed: Biocarta, Reactome, KEGG, GO. We
found that miR-429 directly or indirectly interacts with
proteins involved in processes related to physiological and
pathological functions of the nervous system (e.g., devel-
opment and differentiation of neurons, synaptic and post-
synaptic transmission and plasticity, neurodegenerative
diseases), (Hypergeometric test; Benjamini & Hochberg
FDR Correction; p ≤ 0.01) (Fig. 4).
Discussion
Within cells, miRNAs perform a critical biomolecular
role as master regulators of networks and pathways. Nu-
merous studies have demonstrated that the genes encod-
ing them are causally implicated in neurodegenerative
diseases (e.g., Parkinson’s Disease [23], Alzheimer’s Dis-
ease [24], Huntington’s Chorea [25], Frontotemporal
Dementia [26]). They also are causally involved in
neuropsychiatric disorders (e.g., Schizophrenia [27], Bi-
polar Disorder [28], Autism [29]). Circulating miRNAs
have been already reported as potential markers of these
diseases [18–21]. Tourette syndrome was the first
neuropsychiatric disease etiologically linked to miRNAs,
when TS patients were reported to have a mutation in
the binding site of miR-189 at the 3’ UTR of the
SLITRK1 gene [30]. This finding was not followed by fur-
ther characterization of miRNAs role in TS; furthermore,
no data on cmiRNAs related to TS have been published to
date. Notwithstanding the uncertainty on their tissues of
origin, the discovery of cmiRNAs has opened new exciting
Table 2 Neuropsychological findings
TS NC p-value*
DCI 88.7 % (±7.8)
YGTSS
Total Tic Score 29.7 (±7.1)
Impairment 27.9 (±8.7)
C-YBOCS 18.3 (±8.7)
CONNERS 18.8 (±2.7) 7.5 (±2.4) 0.000
CDI 8.6 (±5.4) 7.3 (±2.6) 0.370
MASC 44.8 (±13.7) 41.8 (±17.2) 0.478
CBCL
Tot 32.7 (±7.4) 22.1 (±6.2) 0.000
Int 9.9 (±2.9) 8.1 (±2.2) 0.028
Ext 10.9 (±2.6) 8.8 (±2.7) 0.002
DCI: Diagnostic Confidence Index
YGTSS: Yale Global Tic Severity Scale
C-YBOCS: Children-Yale Brown Obsessive Compulsive Scale
CDI: Child Depression Inventory
MASC: Multidimensional Anxiety Scale for Children
CBCL: Child Behavior Check-List; Tot: Total; Int: Internalizing; Ext: Externalizing
Standard Deviation is shown between parenthesis
*statistical significance p < 0.05
Fig. 1 Single TaqMan assays for miR-429. Box plots describing the
expression of miR-429 in TS patients and NCs. y-axis represents the-ΔCt
of miRNA. P-values for Wilcoxon rank sum test and t-test are reported
above the boxes
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research perspectives for the identification of the biomo-
lecular bases of pathologic phenotypes [16, 31, 32]; it also
promises important translational applications to clinical
diagnosis and therapy [33, 34]. In fact, cmiRNAs are
endowed with many characteristics that confer them the
properties of good biomarkers. They are easily detect-
able by commonly applied analytical methods as qRT-
PCR [34]. They also are much more stable than
mRNAs in body fluids, possibly due also to their inclusion
in nucleoprotein complexes [35] or encapsulation in
microvescicles and exosomes [36, 37]: accordingly, cmiR-
NAs are resistant to harsh condition, as multiple cycles of
freezing - thawing, boiling, very low or high pH, extended
storage. Profiling data on cmiRNAs in patients with
neuropsychiatric disorders have been already reported for
bipolar disorder [20], schizophrenia [21] and depression
Fig. 2 Receiver Operator Characteristic (ROC) Curve for miR-429 expression in TS patients. ROC curve of miR-429 DCts for TS detection. Gray curve
represents DCts calculated by using miR-320 as endogenous control
Fig. 3 Correlation between miR-429 expression and clinical parameters. Box plots describing the expression of miR-429 in TS patients separated
in comorbidity groups and NCs. y-axis represents the –ΔCt of miRNA. P-values for t-test are reported above the boxes
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[22]. For these pathologies, clinical diagnosis is currently
based on DSM-V criteria (Diagnostic and Statistical Man-
ual of Mental Disorders, fifth edition): profiling of cmiR-
NAs, after a liquid biopsy, offers a new potentially very
important molecular diagnostic tool. Our study is the first
report on profiling of miRNAs transcriptome in serum
from TS patients. Our experiments allowed us to identify
the statistically significant downregulation of cmiR-429 in
serum from TS patients: this allowed us to discriminate
TS patients from unaffected controls. In fact, ROC curve
analysis suggests that this miRNA could be considered a
good marker to diagnose TS, as its sensitivity is 95 % and
its specificity is 42 %. Finally, our data show a statistically
significant positive association between miR-429 ex-
pression and Conner’s ADHD, suggesting a molecular
relationship between biological processes regulating at-
tentional control and inhibitory control (e.g., dopamine
and norepinephrine pathways) and circulating miRNA
expression. MiR-429 is a member of miR-200 family
(i.e., miR-141, -200a, -200b, -200c, miR-429), which
has been shown to inhibit the epithelial–mesenchymal
transition by downregulating ZEB1 and ZEB2 [38, 39].
Interestingly, the genes encoding miR-200a, miR-200b
and miR-429 itself are located at 1p36.33, a genomic
region with copy number variants that has been recently
associated to Autism [40, 41]. The potential involvement
of miR-429 in Autism is intriguing, as it has been sug-
gested that TS, ADHD, ASD (Autism Spectrum Disorders),
and OCD share a common genetic background [42, 43].
By directly targeting the pluripotency factor Sox2 and the
cell-cycle regulator E2F3 in neural stem/progenitor cells,
members of miR-200 family promote cell-cycle exit and
neuronal differentiation of ventral midbrain/hindbrain
neural progenitors, including midbrain dopaminergic neu-
rons [44]. Further, data on mice treated with cocaine sug-
gest that the expression of miR-429 could be involved in
dendritic morphology and synaptic plasticity [45].
Altogether, these data strongly suggest that miR-429 may
be involved in molecular circuits, which control several
aspects of midbrain and hindbrain differentiation and syn-
aptic transmission: this is nicely highlighted by our com-
putational analysis of the molecular network centered on
miR-429 targets (Fig. 4). The potential importance of these
results is stressed by the results of several studies, which
have reported alterations in TS of molecular pathways
controlling regional boundary formation during brain de-
velopment, including their essential role in midbrain-
hindbrain boundary formation [46–48], and proposed that
dopaminergic and serotonergic genes are involved in TS
etiopathogenesis [49].
Conclusions
Based on our data, we propose that miR-429 is a prom-
ising biomarker for minimally invasive molecular diag-
nosis of TS: accordingly, it should be added to classical
diagnostic clinical methodologies. Interestingly, our net-
work analysis shows that miR-429 targets are involved in
critical aspects of neurodifferentiation and synaptic
Fig. 4 Biological Processes controlled by miR-429 network. Overrepresented biological functions from a molecular network built on validated
miR-429 targets, retrieved by different annotation databases (Biocarta, Reactome, KEGG, GO). Data are shown as – log10 of p-values for each
biological process
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transmission: these findings open the way to further mo-




This study was conducted according to the Declaration
of Helsinki and was approved by the Institutional Review
Board of the University of Catania; a written informed
consent was obtained from each study participant.
Patients recruitment
Peripheral blood samples were collected from 58 young
Caucasian people affected by TS [age range 6–17 y;
mean age 12.7 y (SD ±0.9), sex M:F = 50:8] and com-
pared with 18 NCs [age range 10–15 y; mean age 12.2 y
(SD ± 0.9), sex M:F = 14:4]. TS patients presented an age
of onset of 5.9 years (SD ± 1.91): they were recruited and
clinically studied at the Neuropsychiatric Unit, Section
of Child Neurology and Psychiatry, Department of Clin-
ical and Experimental Medicine, University of Catania,
Catania, Italy, EU. NCs were volunteers recruited from
local schools. Demographics are reported in Table 1.
Neuropsychological procedures
Upon collecting basic demographic data, diagnosis of TS
and associated clinical conditions was made in accord-
ance to DSM-V criteria by child neurologists with exten-
sive specific experience (RR and her Collaborators). All
TS patients were initially assessed by using a semi-
structured interview (i.e., the National Hospital Inter-
view Schedule for Gilles de la Tourette Syndrome) [50]
and DCI [51]. Patients with TS and NCs completed the
WISC-III [52], YQOL-R [53], MASC [54], CDI [55],
CADS [56], and the Child Behavior Checklist (CBCL)
[57]. MASC and CDI were used to assess anxiety and
depression, CADS provided an indication of symptoms
related to ADHD, and CBCL was used to assess a range
of emotional and behavioral difficulties. TS patients
underwent two additional clinician-rated interviews: the
YGTSS [58], to measure the severity of tics, and the
Y-BOCS [59] to assess symptoms related to OCD. The
YGTSS is an 11-item clinician-rated interview of motor
and phonic tic severity. The clinician initially notes the
presence of motor and phonic tics based on child and par-
ent report over the past week, as well as behavioral obser-
vations. Following this, the clinician rates the severity of
motor and phonic tics on five separate dimensions each:
number, frequency, intensity, complexity and interference.
These scales score rating from 0 to 50. The YGTSS also
includes a separate impairment rating scale also rated
from 0 to 50. Higher scores indicate the presence of severe
symptoms and impairment. The CY-BOCS is the most
used and reproducible instrument to assess the severity of
obsessive-compulsive symptoms in children. The clinician
initially notes the presence of obsessions and compulsions
based on child and parent report over the past week, as
well as behavioral observations. Following this, the
clinician rates the severity of obsessions and compul-
sions on separate dimensions each: number, frequency,
intensity, resistance and interference. Three index
scores are obtained: Obsession score, Compulsion
score and Total score. The total score evaluates the im-
pairment that obsessive - compulsive symptoms caused
to the patient. Based on the total score, the results can
be interpreted as follows: 0–7 sub-clinical; 8–15 mild;
16–23 moderate; 24–31 severe; 32–40 extreme. Patients
scoring in the mild range or higher are likely experiencing
a significant negative impact on their quality of life.
Entry criteria
We included in this study TS patients who presented nor-
mal IQ (tested with Wechsler Scale). Initial diagnosis was
confirmed after one year: patients who were unable to be
fully assessed at the initial evaluation and/or at follow-up
were excluded. Moreover, we excluded all patients who
showed evidence of severe neurological or physical im-
pairment. Our cohort was comprised of TS patients who
presented DCI > 80 %. NCs were defined as individuals
who had neither chronic diseases nor psychiatric disor-
ders; they were matched for age, sex and ethnic group.
Sample processing
Peripheral blood samples (3 ml) from patients and con-
trols were drawn in the morning, using a butterfly device
inserted into collection tubes equipped with Clot activa-
tor and gel for serum separation (BD Biosciences). Col-
lection tubes were treated according to current
procedures for clinical samples [60]. To separate serum
from cellular components, tubes were rotated end-over-
end at 20 °C for 30’; they were then centrifuged at
4000 rpm in a Beckman J2-21, at 4 °C for 15’, to spin
down blood cells. Supernatant was isolated and centri-
fuged again at 5000 rpm, at 4 °C for 10’, to remove cir-
culating cells or debris [61]. Serum samples were
aliquoted into 1.5 mL, RNase-free, Eppendorf tubes and
stored at −80 °C until analysis. Sera were analyzed with
a Multiscan Ascent microplate reader spectrometer
(Thermo Fisher Scientific) at λ = nm 414, setting an ab-
sorbance value < 0.2 as cut-off [61], to distinguish hae-
molyzed from non-haemolyzed sera.
RNA extraction
RNA was extracted from 400 μl serum samples by using
a Qiagen miRNeasy Mini Kit (Qiagen, GmbH, Hilden,
Germany), according to Qiagen Supplementary Protocol
for purification of small RNAs from serum and plasma.
RNA was eluted in a 40 μl total volume of elution buffer
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with two consecutive steps of elution (30 ul followed by
other 10 μl) in the same collection tube. RNAs were
quantified by spectrophotometry.
miRNAs profiling
To profile the transcriptome of 754 different human miR-
NAs, 4.5 μl of RNA (corresponding to 30 ng of RNA)
were retrotranscribed and preamplified according to man-
ufacturer’s instructions. Preamplified products were
loaded on TLDA, TaqMan Human MicroRNA Array v3.0
A and B (Applied Biosystems, Foster City, CA). PCR reac-
tions on TLDA were performed on a 7900HT Fast Real
Time PCR System (Applied Biosystems). To obtain an ac-
curate miRNA profiling, we used the global median
normalization (GMN) method. Similar to microarray ana-
lysis, Ct values from each sample were normalized to the
median Ct of the array [62, 63]. By computing the Pearson
correlation among the Ct medians and means of each
array and Ct of each miRNA, we identified a miRNA that
showed an expression profile closer to the median and
mean of TLDAs: miR-320. Expression fold changes were
calculated by the 2 −ΔΔCT method [62, 63]. Differentially
Expressed (DE) miRNAs were identified by Significance of
Microarrays Analysis (SAM) (http://www.tm4.org), apply-
ing an unpaired test among ΔCt and using a p-value based
on 100 permutations; imputation engine: K-nearest neigh-
bours (10 neighbours); false discovery rate (FDR) < 0.15.
Validation with single Taqman assays
Purified RNAs from sera of 52 TS patients and 15 NCs
(validation set) were used for miRNA-specific reverse
transcription to obtain miRNA-specific cDNAs. RT-PCR
analysis was performed by using TaqMan MicroRNA
Assays (Applied Biosystems) specific for DE miRNAs
and for controls.
Statistical analyses
All statistical analyses were performed using the SPSS
software (Version 22.0, SPSS, Chicago, IL). Parametric
independent Student t-test and non parametric Wil-
coxon test were used to compare miRNAs serum levels
between the TS patients and NCs. DCts for miR-429 re-
spect to endogenous control miR-320 were used to gen-
erate a Receiver Operating Characteristic (ROC) curve.
Area Under the Curve (AUC) and 95 % confidence in-
tervals (95 % CIs) were calculated to assess the accuracy
of each parameter (sensitivity and specificity) and to find
an appropriate cut-off point. Statistical significance was
established at a p-value ≤ 0.05.
Computational Analysis
Validated targets of miR-429 were retrieved by miRTar-
Base (http://mirtarbase.mbc.nctu.edu.tw/). The corre-
sponding biological network was built by retrieving
interactome data through MiMi Plugin of cytoscape
(http://mimiplugin.ncibi.org/). The tool FatiGO (http://
babelomics3.bioinfo.cipf.es) was applied to determined the
statistical overrepresentation for Gene Ontology (GO),
KEGG and BioCarta terms of miRNAs targets network.
Additional file
Additional file 1: Delta Ct obtained by global median normalization
method for TLDA Panel A and B. (XLSX 72 kb)
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